{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:50:02Z","timestamp":1794963002433,"version":"4.9.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,7]]},"abstract":"<jats:p>Third-generation cephalosporins are widely used and can cause side effects like nausea, vomiting, loss of appetite, and stomach pain. Hypersensitivity reactions and drug-induced immune hemolytic anemia may also occur. This study investigates adverse events associated with these drugs using the FDA adverse event reporting system database. This descriptive study assessed adverse events linked to third-generation cephalosporins reported to the Food and Drug Administration. The data was analyzed descriptively and presented as numbers and percentages in tables, each corresponding to a specific third-generation cephalosporin. The most reported adverse events of cefotaxime were pain, eosinophilia, and ineffective drugs. Ineffective medication, pyrexia, and sepsis were the most frequently reported adverse effects of ceftazidime. The most reported events of cefdinir were diarrhea, drug hypersensitivity, and rash. The most reported events of ceftriaxone included off-label use, ineffective drugs, and eosinophilia. The most reported events of cefpodoxime included pyrexia, pruritus, and diarrhea. The most reported events of cefoperazone were a decreased prothrombin level, hemorrhage, and pyrexia. The most reported adverse events of cefixime included diarrhea, clostridium colitis, and ineffective drugs. This study highlights that gastrointestinal issues, hypersensitivity reactions, and inadequate medication responses are the most commonly reported adverse effects of third-generation cephalosporins. Despite their effectiveness in treating various infections, healthcare professionals must remain vigilant about the potential side effects of these drugs.<\/jats:p>","DOI":"10.1097\/md.0000000000045778","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T18:01:42Z","timestamp":1762538502000},"page":"e45778","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Adverse events associated with third-generation cephalosporins: Analysis of the FDA adverse event reporting system database"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4215-6225","authenticated-orcid":false,"given":"Nehad J.","family":"Ahmed","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R4-20260729","doi-asserted-by":"crossref","first-page":"299","DOI":"10.31083\/ph.2022.2408","article-title":"Drug-induced weight gain in the last 10 years: a descriptive study.","volume":"77","author":"Ahmed","year":"2022","journal-title":"Die Pharmazie"},{"key":"R5-20260729","first-page":"2303","article-title":"A descriptive study of drug-induced clostridium difficile.","volume":"41","author":"Ahmed","year":"2022","journal-title":"Lat Am J Pharm"},{"key":"R6-20260729","first-page":"127","article-title":"Adverse drug reactions associated with the most prescribed antibiotics.","volume":"42","author":"Ahmed","year":"2023","journal-title":"Lat Am J Pharm"},{"key":"R7-20260729","doi-asserted-by":"crossref","first-page":"106159","DOI":"10.1016\/j.ijantimicag.2020.106159","article-title":"Emergence of Haemophilus parainfluenzae resistant to third-generation cephalosporins in Italy: potential role of PBP3 and PBP5 substitutions in high-level resistance.","volume":"56","author":"Principe","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"R8-20260729","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum beta-lactamases: a clinical update.","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"R9-20260729","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/archinte.162.2.185","article-title":"Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species.","volume":"162","author":"Cosgrove","year":"2002","journal-title":"Arch Intern Med"},{"key":"R10-20260729","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/femsre\/fuz014","article-title":"Antibiotic resistance breakers: current approaches and future directions.","volume":"43","author":"Laws","year":"2019","journal-title":"FEMS Microbiol Rev"},{"key":"R11-20260729","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3904\/kjim.2014.29.1.27","article-title":"Third-generation cephalosporin resistance in gram-negative bacteria in the community: a growing public health concern.","volume":"29","author":"Park","year":"2014","journal-title":"Korean J Intern Med"},{"key":"R12-20260729","doi-asserted-by":"crossref","first-page":"e01076","DOI":"10.1128\/AAC.01076-18","article-title":"Past and present perspectives on \u03b2-lactamases.","volume":"62","author":"Bush","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R13-20260729","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.diagmicrobio.2006.12.002","article-title":"Adverse events associated with the use of oral cephalosporins\/cephems.","volume":"57","author":"Mitropoulos","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R14-20260729","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3390\/ph14050425","article-title":"Signal detection of adverse drug reactions of cephalosporins using data from a national pharmacovigilance database.","volume":"14","author":"Choi","year":"2021","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"R15-20260729","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1517\/14740338.7.3.295","article-title":"Hypersensitivity reactions to cephalosporins.","volume":"7","author":"Moreno","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"R16-20260729","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.jaip.2019.06.001","article-title":"Cephalosporin allergy: current understanding and future challenges.","volume":"7","author":"Khan","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R17-20260729","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.jaip.2020.11.063","article-title":"Cephalosporin hypersensitivity: descriptive analysis, cross-reactivity, and risk factors.","volume":"9","author":"Touati","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R18-20260729","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.anai.2010.06.014","article-title":"Use of commercial anti-penicillin IgE fluorometric enzyme immunoassays to diagnose penicillin allergy.","volume":"105","author":"Macy","year":"2010","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:02:04Z","timestamp":1785351724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":15,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045778","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"2024-12-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}